NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001  by Scicinski, Jan et al.
Redox Biology 6 (2015) 1–8Contents lists available at ScienceDirectRedox Biologyhttp://d
2213-23
☆This
Muntan
n Corr
E-mjournal homepage: www.elsevier.com/locate/redoxResearch PaperNO to cancer: The complex and multifaceted role of nitric oxide and
the epigenetic nitric oxide donor, RRx-001$
Jan Scicinski a,n, Bryan Oronsky a, Shoucheng Ning b, Susan Knox b, Donna Peehl c,
Michelle M. Kim d, Peter Langecker e, Gary Fanger a
a EpicentRx, Inc., 800 W El Camino Real, Suite 180, Mountain View, CA 94040, United States
b Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, United States
c Department of Urology, Stanford University, Stanford, CA, United States
d University of Michigan, Radiation Oncology, Ann Arbor, MI, United States
e Los Gatos Pharmaceuticals, Los Gatos, CA, United Statesa r t i c l e i n f o
Article history:
Received 15 May 2015
Received in revised form
30 June 2015
Accepted 1 July 2015
Available online 2 July 2015
Keywords:
Nitric oxide
Radiosensitization
Radiotherapy
Hypoxia
Cancerx.doi.org/10.1016/j.redox.2015.07.002
17/& 2015 Published by Elsevier B.V. This is a
article belongs to a special issue on Nitric Oxid
é and Benjamin Bonavida.
esponding author. Fax: þ1 650 396 4450.
ail address: jscicinski@epicentrx.com (J. Scicina b s t r a c t
The endogenous mediator of vasodilation, nitric oxide (NO), has been shown to be a potent radio-
sensitizer. However, the underlying mode of action for its role as a radiosensitizer – while not entirely
understood – is believed to arise from increased tumor blood ﬂow, effects on cellular respiration, on cell
signaling, and on the production of reactive oxygen and nitrogen species (RONS), that can act as
radiosensitizers in their own right. NO activity is surprisingly long-lived and more potent in comparison
to oxygen. Reports of the effects of NO with radiation have often been contradictory leading to confusion
about the true radiosensitizing nature of NO. Whether increasing or decreasing tumor blood ﬂow, acting
as radiosensitizer or radioprotector, the effects of NO have been controversial. Key to understanding the
role of NO as a radiosensitizer is to recognize the importance of biological context. With a very short half-
life and potent activity, the local effects of NO need to be carefully considered and understood when
using NO as a radiosensitizer. The systemic effects of NO donors can cause extensive side effects, and also
affect the local tumor microenvironment, both directly and indirectly. To minimize systemic effects and
maximize effects on tumors, agents that deliver NO on demand selectively to tumors using hypoxia as a
trigger may be of greater interest as radiosensitizers. Herein we discuss the multiple effects of NO and
focus on the clinical molecule RRx-001, a hypoxia-activated NO donor currently being investigated as a
radiosensitizer in the clinic.
& 2015 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Nitric oxide (NO) is a familiar molecule, having been studied
extensively over the past 3 decades, whose seeming simplicity of
structure has activity impacting nearly every major organ system
[1–3]. NO is a gaseous diatomic radical that readily passes through
biological membranes and is a well characterized vasodilator and
anti thrombotic agent in a cardiovascular setting. Less well un-
derstood are its protean effects and activity, good and bad, ther-
apeutic and harmful, in cancer, which is the subject of this review.
In mammals, under normoxic conditions, NO is generated en-
dogenously ‘on demand’ by the oxidative conversion of Arg to L-n open access article under the CC
e and Cancer, edited by Jordi
ski).citrulline, catalyzed by a variety of nitric oxide synthases (Fig. 1).
These synthases can be divided into functional classes, constitutive
and inducible NOS (cNOS and iNOS), based on calcium sensitivity
[4]. Although the action of NO includes induction of signaling
through nitration of proteins the chief activity is vasodilation
through binding of soluble guanylate cyclase, the primary target of
NO, leading to synthesis of cGMP, the key mediator for down-
stream NO-related signaling. Under hypoxic conditions, NOS ac-
tivity is disabled and NO is synthesized independently through the
hypoxia-speciﬁc nitrite reductase activity of deoxyhemoglobin and
others that effectively catalyze the conversion of serum nitrite to
NO [5]. NO is highly promiscuous, binding with a wide range of
targets resulting in varied and sometimes diverse activity. Meta-
bolism is rapid, with metabolites including species such as per-
oxynitrite and N2O3 that display anti-tumor mechanisms either
alone or in concert with radiation [6,7]. With rapid synthesis, high
permeation and a short half-life, NO is a highly effective moleculeBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. The nitric oxide–nitrite–nitrate pathway. Under normal oxygen parameters
(normoxia), nitric oxide (NO) is produced by NOS from L-Arg. In the absence of
oxygen (hypoxia), nitrite is reduced by a variety reductases, including deox-
yhemoglobin to produce NO. Further reduction/oxidation of NO can lead to pro-
duction of metabolites.
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context-speciﬁc activity.
Resistance to radiotherapy and subsequent recurrence of dis-
ease is a signiﬁcant problem in the treatment of cancer. A key
factor contributing to the observed radioresistance is tumor hy-
poxia [8,9]. Hypoxic tumors can have an aggressive phenotype,
strongly associated with progression, metastasis and chemo and
radioresistance. The reversal of tumor hypoxia to transform the
tumor to a phenotype that is more sensitive to radiation or che-
motherapy has been a major are of research [10].
As a consequence of its local and context-dependent mechan-
ism, the activity of NO as a radiosensitizer is complicated, and in
some cases contradictory, depending very much on context of
activation [11]. The context factors include the local concentration
of NO, the site of action, the oxygenation and architecture of the
local tissue and vessels, in essence, the tumor microenvironment.
This context dependent, complex and highly varied activity of NO
has led to a paradox with contradictory observations on the action
of this species as a radiosenstizer with some articles substantiating
and demonstrating radiosensitizing activity, with others reporting
the opposite [2]. This paradox has been greatly debated, and NO
with its biologically closely related partners, described as ‘the
good, the bad and the ugly’ namely NO, superoxide and perox-
ynitrite respectively [12].
Like a two-edged sword, NO can function both positively and
negatively in a variety of ways: for example NO can function as a
pro and anti-apoptotic agent, promoting or protecting cells from
oxidative stress, and acting both as a radioprotector and
radiosensitizer.
As ‘Il Brutto’ or ‘the bad’, evidence points towards NO as a tu-
mor promoter, with increased expression of iNOS in a number of
human tumors such as pancreatic, breast, gynecologic and head
and neck [13], and strongly suggests NO plays a role in metastasis
as well as growth promotion possibly by enabling increased tumor
blood ﬂow via inducing vasodilation [12,14]. Furthermore, inhibi-
tion of NO synthase was found to decrease tumor blood ﬂow and
induce tumor shrinkage [15].
However, NO as ‘Il Buono’, acting as a hypoxic cell radio-
sensitizer [16] has been described extensively in the literature
with radiosensitizing effects arising from endogenous induction
[16] or through external application of NO-donors [17]. The NOactivity observed was explained through effects on systemic and
hypoxic vasodilation, RBC rheology and decreased oxygen utiliza-
tion. These are discussed in greater detail below.
Since NO activity is heavily dependent on context and con-
centration, the paradoxical activity of this elusive molecule must
be considered multidimensionally, by considering local con-
centration, interaction and reaction with immediate biological
surroundings and metabolism to form other, and often more re-
active, nitrogen oxides. The concentration speciﬁc activity of NO
can be considered as having a series of thresholds: at very low
levels, tumor growth is stunted [18], while relatively moderate
concentrations promote tumor angiogenesis and cell survival [19].
Further increases in local NO concentration above this threshold
switch NO activity to an anti-tumor role [20]. One rationalization
or attribution that could account for these observations is through
the effect of the formation of highly reactive NO metabolites such
as peroxynitrite and N2O3, characterized as ‘Il Cattivo’ or ‘The Ugly’
by Beckman [12]. These reactive oxygen and nitrogen species
(RONS) can go on to induce, directly or indirectly, cellular damage
and changes in microenvironment that lead to apoptosis and can
serve to promote radiosensitization. The concept of multiple
thresholds for NO activity is critical to the understanding of its
radiosensitizing and cytotoxic effects [18,19].
The delivery of nitric oxide to serve as a radiosensitizer needs
to take into consideration local versus systemic effects. Often high
doses of NO donors do not necessarily lead to high local tumor
concentrations of NO, while resulting in systemic side effects such
as hypotension. The local and context-speciﬁc activity of NO as a
radiosensitizer suggests that a NO-mediated radiosensitizer
should, ideally, deliver NO selectively to areas of tumor hypoxia.
This review on NO as a radiosensitizer will therefore describe
some aspects of nitric oxide physiology to place in context the
radiosensitizing effects of this contradictory molecule and then
will focus on the preclinical radiosensitizing effects of RRx-001, a
novel hypoxia mediated and locally acting nitric oxide donor that
is currently being explored in the clinic as a radiosensitizer.2. Radiosensitization effects of oxygen and nitric oxide are
closely linked
Oxygen is intricately linked with radiosensitization. The activity
of radiation is multiplied two to three times in the presence of
excess oxygen, while the most common radiation resistance me-
chanism is related to the low oxygen levels in solid tumors. In-
cident radiation ionizes water molecules leading to the formation
of reactive oxygen species that produce DNA breaks with radical
species at the end of the fragments [10]. Whether this damage
leads to cell death or is repaired depends on whether oxygen is
able to react with the DNA radicals to form peroxy radicals that are
not as readily repaired. In the absence of oxygen, DNA radicals are
quenched through thiol-mediated redox reactions and DNA repair
mechanisms that enable the cell to survive. Consequently, reox-
ygenation of tumors has been extensively investigated as a
radiosensitization strategy [10]. Though beyond the scope of this
review, reoxygenation proved to provide only variable or poor
results as a consequence of the difﬁculty of ensuring diffusion of
oxygen to the hypoxic regions of the tumor [10]. Using an indirect
approach, compounds that mimic the effect of oxygen by donating
radicals that serve to ‘ﬁx’ DNA damage have also been extensively
explored. While many of these compounds did indeed possess
radiosensitizing properties, clinical utility was limited either by
toxicity or low activity [10,21].
In addition to the vasodilating effects of NO that can lead to
greater tumor oxygenation and hence radiosensitization, discussed
in more detail below, as a free radical and source of reactive
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radiosensitizing effects. With comparable electron afﬁnity to
oxygen, nitric oxide would be expected to also ﬁx DNA radiation
damage in a similar way [22]. Indeed, radiation-generated guanine
and adenine radicals reacting with NO in a combination experi-
ment have been shown to result in nitrosation products such as
8-azaguanine, xanthine and 8-azaadenine [23,24]. However, be-
cause of its short half-life and rapid reaction with oxygen and
reactive oxygen species, the radiosensitizing effects of NO are
surprisingly long-lived. This may be due, in part, to the induction
of vasodilation and associated improved diffusion of blood con-
taining oxygen, NO and RONS deep into tumors to potentiate the
effect of radiation [25,26]. Moreover, in the presence of low dose
radiation, NO promotes p53 nuclear retention, sensitizing cells to
apoptosis [27]. The formation of NO metabolites with oxygen and
superoxide such as peroxynitrite [28] drive the enhanced radio-
sensitization effect of NO, enabling the parent molecule to es-
sentially act with a pronounced bystander effect. Relatively small
increases in intratumoral NO can lead to signiﬁcant and prolonged
effects. Peroxynitrite, in particular, can cause multiple cell insults
such as lipid peroxidation, cysteine oxidation, and protein ni-
trosylation leading to apoptotic and necrotic cell death [29]. Thus
the presence of peroxynitrite serves as an important anti-tumor
mediator and radiosensitization mediator [30].3. Indirect NO radiosensitization effects: increasing tumor
oxygenation
While it is indisputable that NO has an effect on tumor blood
ﬂow, the activity observed in different studies has been contra-
dictory. In some instances, observations supported increased tu-
mor perfusion, with enhanced responses to radiation, while other
studies have reported decreased blood ﬂow that was associated
with increased tumor proliferation [31]. For example, a study ad-
ministering a low systemic dose of NO through application of
transdermal nitroglycerin to patients with prostrate cancer re-
ported a lowering of PSA, which was attributed to an increase in
tumor blood ﬂow [20]. Additionally, a promising response rate of
75% was found with concurrent chemoradiation in a Phase 2 study
in locally advanced NSCLC patients treated with cisplatin and vi-
norelbine plus concurrent nitroglycerin with radiotherapy [32].
The differences in observations between studies could be ex-
plained by tumor microenvironment heterogeneity and differ-
ences between tumor types [33]. These contradictory observations
could be rationalized by a redistribution of blood ﬂow through the
‘steal effect’, a consequence on blood ﬂow of a systemic vasodi-
latory response as a result of the administration of a systemic NO
donor. Paradoxically, because tumor vasculature is fully dilated,
NO donation results in an overall redistribution of blood to the
systemic circulation, thus lowering tumor perfusion. Conversely,
an anti-steal effect mediated through systemic vasoconstriction,
for example, could increase blood ﬂow to the tumor [34]. In ad-
dition to direct effects on the vasculature, NO has been shown to
alter red blood cell elasticity and to reverse the surface crenulation
that arises in RBCs after exposure to low oxygen in a similar way to
the effect found in blood storage products [35]. NO donation
would then be expected, therefore, to increase tumor blood per-
fusion by increasing red blood cell elasticity and reducing ﬂow
viscosity, thus enabling the delivery of oxygen into areas of the
tumor that would not be readily oxygenated. These vascular
changes would be expected to increase the efﬁcacy of radiation.
4. Indirect NO radiosensitization effects: the effect of hypoxia
Tumor hypoxia can be described in two different ways: chronichypoxia arises in tissue where blood perfusion is limited and is
characterized by a decreasing oxygen tension gradient that is re-
lated to the distance from functioning blood vessels. Acute hypoxia
however, arises from temporary blockages in blood ﬂow to speciﬁc
parts of the tumor by poor blood vessel patency. While delivering
a blood-borne agent to chronically hypoxic regions is clearly
challenging, it is anticipated that areas of acute hypoxia would be
more sensitive to the vasodilatory and red blood cell viscosity
modifying effects of NO to temporarily ease blockages and allow
entry of blood ﬂow and tissue reoxygenation, leading to an im-
proved radiation response.
NO transport by red blood cells is complex and subject to
contradictory theories. One hypothesized mechanism describes
the transport of NO by hemoglobin with NO bound either to the
heme iron or to a highly conserved residue on the beta chain, the
cysteine 93. The beta Cys-93 residue of hemoglobin is highly
conserved throughout mammalian species and is vital for con-
trolling hemoglobin oxygen afﬁnity and for serving as a key re-
sidue for NO binding and transport [36,37]. This residue is in close
proximity to the His-92 that interacts directly with the heme iron
and thereby closely controls hemoglobin oxygen afﬁnity. Binding
to this residue increases hemoglobin oxygen afﬁnity, allowing for
release of oxygen under greater hypoxia leading to, indirectly,
increased radiosensitization. The transition of hemoglobin from its
oxygenated (R) to deoxygenated (T) form, allows the release of NO
to diffuse, either as the parent or as a S-nitrosothiol, to the vessel
wall inducing the cascade leading to vasodilation, improved blood
ﬂow, oxygenation and, therefore, radiosensitization [38]. An al-
ternative mechanism invokes the role of systemic nitrite that is
reduced under hypoxic conditions by deoxyhemoglobin and other
nitrite reductases to NO [5]. Regardless of transport and source of
NO, both these competing hypotheses describe NO being delivered
to areas of hypoxia to facilitate vasodilation and allow oxygen
transport.
Under hypoxia, HIF-1 alpha [39], one of the primary responses
to hypoxia, is stabilized and induces the expression of proteins
important to the hypoxic response such as VEGF, GLUT2 and
others, stabilizing the low oxygen phenotype and hence promot-
ing resistance to radiation [10]. Acting directly on the mitochon-
drial respiratory chain through cytochrome c oxidase [1], NO and
its metabolites (e.g. nitrate) inhibit mitochondrial respiration [40],
leading to lower oxygen consumption [41]. This results in an in-
crease in oxygen availability to targets that are not part of the
respiratory chain [42] such as HIF-1 alpha. Thus NO mediated re-
oxygenation and lower oxygen use can lead to increased radio-
sensitivity [41] through the reversal of HIF-1 alpha stabilization
and suppression of the hypoxic response [43].5. Nitric oxide as a radioprotectant
Paradoxically, in addition to the extensive literature supporting
the role of NO as a radiosensitizer, there have been a smaller
number of reports suggesting a role for NO as a radioprotectant.
Studies have demonstrated a greater survival of mice that were
exposed to whole body radiation after treatment with the NO
donor DEA/NO [44], while a number of papers have described the
blocking of CD47 and TSP-1 interactions, thereby increasing NO
levels, as a successful strategy to protect mice from the effects of
total body irradiation [45,46]. Indeed CD47 deﬁcient animals were
observed to be less sensitive to the effects of radiation [47]. In-
terestingly, targeting of CD47 was reported by Maxhimer as re-
sulting in both radiosensitization of tumors and radioprotection of
normal tissue [45], an observation of potential relevance to the
activity of RRx-001 described below. With thrombospondin-1 and
CD47 closely linked to the activity of NO, a role for NO in
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potheses suggest that radioprotection arises from the induction of
autophagy [47], by changes in local tumor blood ﬂow or by a
systemic ‘steal’ effect leading to lower oxygen delivery to bone
marrow and, paradoxically, inducing a local hypoxia-mediated
protective response [44]. In addition, the quenching of RONS by
reaction with increased levels of NO could confer a direct anti-
oxidant effect [48] as evidenced by increased nuclear translocation
of Nrf2, a key member of the antioxidant response element, that
results in expression of redox quenchers such as glutathione [49].6. Radiosensitization strategies based on NO
As discussed above, systemic NO-donors have been shown to
be radiosensitizers: while radiosensitization with NO gas itself has
been demonstrated [50,51], the use of NO donors such as DEA/NO
[52], the nitroxyl donor Angeli salt [53], DETANONOate [54],
spermine nonoate [22] or isosorbide dinitrate [55] is more com-
mon. In addition to radiosensitization, in the studies of these NO
donors, increases in tumor blood ﬂow were also observed when
the administration of NO synthase inhibitors led to radioresistance
[55]. However, in other studies NO donors, in this case ni-
troprusside [56], resulted in a vascular steal effect, as described
above, manifested by a drop in mean arterial blood pressure. Other
studies have reported similar results: NO donors that have been
reported elsewhere to be radiosensitizers that increased tumor
blood ﬂow, were also found to lower tumor oxygenation through a
steal effect [57].
Although these reports highlight the inconsistent and some-
time contradictory effects of NO on tumor blood ﬂow, a conclusion
that can be drawn from these publications is that the systemic
effects of NO can greatly inﬂuence local intratumoral activity. One
strategy that could circumvent the steal effect and lead to poten-
tially better radiosensitization results would be to deliver NO in
such a way that it would be released or produced in the tumor
microenvironment, thereby affecting local vasodilation and RONS
production without systemic effects.
A number of strategies to deliver or generate NO locally have
been investigated. In addition to RRx-001, which delivers NO to
the tumor under hypoxia (discussed below), approaches that in-
duce the local production of NO by driving the iNOS gene have
shown promise. In addition to exploiting the cytokine induced
upregulation of iNOS, resulting in local NO synthesis [21], many of
these approaches have explored using transfected viral vectors
encoding human iNOS. For example, transfecting the iNOS gene
under the control of a constitutive cytomegalovirus immediate
early promoter resulted in signiﬁcant production of NO in vitro
under hypoxic, but not normoxic conditions [58]. Other strategies
such as ‘radiogenic therapy’ [59] achieve iNOS gene transfer using
WAF-1 [16] or pE9 [60] radiation-inducible promoters, essentially
using the presence of incident radiation to activate NO production.Fig. 2. RRx-001: structure and primary metabo7. Local delivery of nitric oxide by RRx-001
RRx-001 is an aerospace industry-derived anti-cancer agent
that acts as an ROS and RNS-mediated epigenetic modulator that
has completed a Phase 1 ﬁrst in human study [61] and is currently
in Phase 2 clinical development. RRx-001 (Fig. 2) has also been
reported to have radiosensitizing anti-tumor properties while
acting as a radioprotectant in normal tissue. RRx-001 differs from
other NO-donating compounds in that the molecule induces local,
endogenous and biphasic production or release of NO, rather than
fragmenting to release NO systemically. This activity is closely
linked to the metabolism of RRx-001. Metabolic and disposition
studies on RRx-001 have shown that, on infusion, the compound
rapidly, irreversibly and selectively binds to hemoglobin at a key
NO binding site, the beta-cysteine 93 residue described above [62]
(Fig. 3) and with glutathione [63,64] indirectly increasing oxida-
tive stress [65]. While the RRx-001 glutathione adduct is rapidly
excreted, RRx-001-bound hemoglobin remains in circulation for
the duration of the lifetime of the red blood cell (Fig. 4).
NO release is biphasic: initial release occurs immediately on
infusion, presumably due to the displacement of NO from the RRx-
001 binding site on hemoglobin. The release is rapid and transient
resulting in local vasodilation that resolves on cessation of infu-
sion. Deoxygenated hemoglobin can act as an efﬁcient nitrite re-
ductase, catalyzing the reduction of serum nitrite to NO under
hypoxic conditions and compensating for the inactivity of nitrite
synthetase activity under hypoxia [67–69]. In the small sub-set of
red blood cells that contain RRx-001 bound hemoglobin, the
production of NO under hypoxic conditions is greatly potentiated
[67], resulting in an overproduction of NO in deeply hypoxic tissue,
particularly in tumors subject to acute hypoxia.
As has been shown above, NO can act as an efﬁcient radio-
senstizer. With RRx-001 delivering NO and ROS at the right time
and in the right place through the ampliﬁcation of hypoxia-
mediated deoxyhemoglobin nitrite reductase activity, RRx-001 has
been shown to possess marked radiosensitizing properties.
The radiosensitizing effects of RRx-001 were studied in cellular
assays and in animal models [70]. RRx-001 was found to be a
potent radiosensitizer in vitro, in multiple cell lines, with radiation
dose modiﬁcation factors (DMF) of 1.7 and 1.6 for HT29 and SCCVII
cell lines respectively (Fig. 5). Radiation survival was studied under
both hypoxic and normoxic conditions with RRx-001, and RRx-001
was found to increase the response of radioresistant hypoxic cells
with a DMF of 1.9, suggesting an enhanced radiosensitizing effect
of RRx-001 under hypoxia.
In vivo, the radiosensitizing effect of RRx-001 was studied in
syngeneic tumor models [71]. Dosing RRx-001 at 5 or 6 mg/kg
daily in combination with local tumor radiation at 250 or 400 cGy
resulted in an enhancement of the effect of the local tumor irra-
diation, with a signiﬁcant increase in the tumor growth delay time
compared to untreated controls as well as mice treated with either
RRx-001 or radiation alone (Fig. 6). Although as a single agent,
RRx-001 inhibited tumor growth, the tumor growth delay ob-
served in the combination therapy was signiﬁcantly greater and
was determined to be synergistic. Animals dosed with RRx-001 aslites (Hb: hemoglobin, GSH: glutathione).
Fig. 3. Molecular model of RRx-001 bound to the beta-Cys-93 of deoxyhemoglobin
showing proximity to heme.
Fig. 4. NO release from RRx-001 treated RBCs. Left: schematic of reduction of
serum nitrite to nitric oxide by RRx-001-bound hemoglobin. Right: RRx-001 po-
tentiates the nitrite reductase activity of hemoglobin. Rate of NO formation of nitric
oxide from nitrite compared to controls (Fens et al. [66]).
Fig. 5. Combination of RRx-001 and radiation. XRT alone or in combination with
RRx-001 in HT-29 cells (Po0.01) (left) and SCCVII cells (right) (Po0.01).
Fig. 6. Tumor growth curves in mice showing the effect of a combination of RRx-
Fig. 7. Time and sequence dependence of the radiosensitizing effect of RRx-001
showing the relationship between 4 TGD and the dosing schedule of RRx-001
and radiation. RRx-001 was dosed at t¼0, 72, and 724 h. Total body radiation
(7 Gy) was administered at t¼0 h.
Fig. 8. Microbubble ultrasound imaging of tumor blood ﬂow in mouse. Perfusion
rate reaches a maximum at 6 h with the effect persisting for at least 48 h.
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overt systemic toxicity as determined by weight loss and no sig-
niﬁcant hematological, biochemical, or histopathological changes
were observed [70,71].
The effects of sequence and timing of RRx-001 radio-
sensitization were also investigated. In a SCCVII syngeneic mouse
tumor model, RRx-001 was administered at the same time, or
2 and 24 h before and after a single dose of 7 Gy to the tumor. The
maximal radiosensitizing effect was found to occur when RRx-001
was administered between 0 and 2 h before radiation (Fig. 7).
As discussed above, the radiosensitizing effects of NO and NO
donor molecules can result from changes in tumor blood ﬂow in
addition to the direct effects of NO metabolites. RRx-001 was
found to modify tumor blood ﬂow. Using contrast-enhanced ul-
trasound, increases in tumor blood ﬂow and perfusion were ob-
served in mice bearing SCCVII tumors for up to 48 h post dose with
ﬂow peaking at 6 h (Fig. 8) [70].
Abdominal and pelvic tumors are often treated with radio-
therapy but the dose of radiation that can be safely administered is
limited by the sensitivity of the GI epithelium to radiation, which
can result in both acute GI toxicity, as well as late effects such as
ﬁbrosis, obstruction and perforation [72]. The determination of001 with radiation (Po0.05 between combination and single agent groups).
Fig. 9. Radioprotection of intestinal crypt cells by RRx-001. Mean crypt cells per duodenum (left) and jejunum (right) sections compared to TBI only dose. ♦¼TBI;
□¼TBIþRRx-001.
J. Scicinski et al. / Redox Biology 6 (2015) 1–86whether or not a potential radiosensitizer could result in addi-
tional toxicity arising from sensitization of normal GI epithelium is
therefore important. Since the survival of intestinal crypt cells is a
very sensitive method for determining radiation-induced toxicity
to the intestine, the intestinal crypt cell assay was used to de-
termine the effect of RRx-001 on intestinal epithelium [73]. In
these experiments, mice were exposed to total body radiation of
10–15 Gy in combination with RRx-001. RRx-001 was found to
have a radioprotectant effect on stem cells in the duodenum, ileum
and jejunum, with a higher number of viable crypt cells at the end
of the experiment in the mice treated with RRx-001 prior to ir-
radiation compared to mice treated with radiation alone (Fig. 9).8. Conclusions
The roles of nitric oxide and oxygen in the context of radio-
sensitization are deeply intertwined with nitric oxide (NO), which
can facilitate the permeation of oxygen into hypoxic areas and
control oxygen function and reactivity. This close relationship
suggests that nitric oxide donors can play an important role as
radiosensitizers, and that manipulation of the balance of nitric
oxide and oxygen can be an effective mechanism of tumor radio-
sensitization. However, given the often contradictory and con-
founding results from many studies, use of current NO donor
chemotypes as radiosensitizers is fraught with difﬁculties, with
mixed results and systemic toxicity. Therefore, further research
into the mechanism of NO-mediated radiosensitization, as well as
the discovery of a new generation of NO donors is needed to im-
prove the therapeutic index of this approach. With the growing
understanding of the context-speciﬁc activity of NO, research into
novel NO donor radiosensitizers should focus on approaches that
selectively increase the local concentration of NO in tumors. This
approach would be anticipated to result in selective local effects in
tumors, with little or no effect on systemic circulation or blood
pressure, and would be widely applicable to different tumor types.
Such a strategy could mitigate the effects of tumor hypoxia and
associated downstream effects, thereby addressing an importantunmet need in cancer therapy. Novel agents, such as the small
molecule RRx-001, that deliver NO selectively to tumor tissue,
while sparing normal tissue with negligible systemic side effects,
represent an exciting new direction for the development of
radiosensitizers in the future, that may have the potential to sig-
niﬁcantly increase the therapeutic index of radiation therapy.Attributions
Figs. 5–9 are adapted (or reprinted) by permission from the
American Association for Cancer Research [S. Ning, et al., Dini-
troazetidines are a novel class of anticancer agents and hypoxia-
activated radiation sensitizers developed from highly energetic
materials, Cancer Res. 14(72) (2012) 2600–2608].Acknowledgments
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